Key result
Heart transplantation is an established and effective treatment for end-stage Chagas cardiomyopathy, with survival rates often exceeding those of other etiologies despite the risk of T. cruzi reactivation.
Why the study?
In patients with Chagas disease undergoing heart transplantation, immunosuppressive therapy can reactivate Trypanosoma cruzi infection and compromise outcomes, requiring early diagnosis and treatment.
Heart transplantation is an effective treatment for end-stage Chagas cardiomyopathy with favorable survival rates, provided that T. cruzi reactivation is rigorously monitored and treated.
May support transplantation for end-stage Chagas cardiomyopathy; leaves open need for higher-level evidence on reactivation management.
Heart transplantation (HT) is an established treatment for patients with advanced heart failure (HF). Chagas disease (CD), caused by the Trypanosoma cruzi (T.cruzi) is an important cause of HF in Latin America. Considering CD is a chronic infectious disease, the use of immunosuppressive therapy after HT can reactivate T. cruzi infection and compromise outcomes. Early diagnosis and treatment of this complication is extremely important, which requires knowledge, experience, and a high degree of suspicion by transplant physicians. Furthermore, with [...]
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2020) conducted a review in Chagas Cardiomyopathy. Heart Transplantation was evaluated. Heart transplantation is an established and effective treatment for end-stage Chagas cardiomyopathy, with survival rates often exceeding those of other etiologies despite the risk of T. cruzi reactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: